Briefing on the Fundamentals of Johnson & Johnson

By Harris Dyer • Wednesday, March 13 10:10 • Permanent Link

Johnson & Johnson, a Large-Cap Pharmaceutical stock, moved -0.6% this morning. Here are some facts about the company that we're keeping an eye on:

Johnson & Johnson has logged a 5.4% 52 week change, compared to 33.0% for the S&P 500
JNJ has an average analyst rating of buy and is -7.7% away from its mean target price of $175.19 per share
Its trailing earnings per share (EPS) is $5.21, which brings its trailing Price to Earnings (P/E) ratio to 31.0. The Health Care sector's average P/E ratio is 30.21
The company's forward earnings per share (EPS) is $11.04 and its forward P/E ratio is 14.6
The company has a Price to Book (P/B) ratio of 5.66 in contrast to the Health Care sector's average P/B ratio is 4.08
The current ratio is currently 1.2, which consists in its liquid assets divided by any liabilities due within in the next 12 months
JNJ has reported YOY quarterly earnings growth of 10.6% and gross profit margins of 0.7%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.